Abstract
Many studies seek to define the appropriate margin width necessary to confer the best survival advantage following hepatic resection for colorectal metastatic disease. The ability to achieve at least a 1-cm tumor-free margin has historically represented one of the strongest prognostic factors determining overall outcomes and has been a necessary condition for resectability. With the advent of modern chemotherapy, the importance of surgical margin width is increasingly questioned and our understanding of its impact is evolving concomitantly to the improvement and the widespread use of more effective systemic chemotherapeutic agents. Although achieving a microscopic margin-negative resection (R0) remains the goal of surgical resection, specific tumor biology factors should be consider in deciding on the appropriate margin width. In this review, we summarize the most recent evidence regarding the importance of the surgical margin in hepatic resection for colorectal metastasis in the era of modern chemotherapy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Adam R et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. The Oncologist 2012;17:1225–1239.
Vigano L et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol. 2014;21:1276–86. This study assesses the risk of early recurrence after liver resection for colorectal metastases and its prognostic value. Although early recurrence negatively affects prognosis, re-resection may restore better survival.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18. discussion 318–21.
Minagawa M et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–99.
Choti MA et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.
Andreou A et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013;257:1079–88. This study sought to determine the impact of surgical margin status on overall survival of patients undergoing hepatectomy for colorectal liver metastases after modern preoperative chemotherapy. The impact of positive margins is most pronounced in patients with suboptimal response to systemic therapy.
Ekberg H et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73:727–31.
Cady B et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg. 1992;127:561–8.
Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.
Nordlinger B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.
Tzeng C-WD, Aloia TA. Colorectal liver metastases. J Gastrointest Surg. 2013;17:195–201.
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Gruenberger T et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702–8.
Wong R et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042–8.
Wakai T, Shirai, Y, Sakata J, Valera V A. Appraisal of 1 cm hepatectomy margins for intrahepatic micrometastases in patients with colorectal carcinoma liver metastasis. Ann Surg. 2008;15(9):2472–81.
Kato T et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:S22–31.
Wray CJ et al. The significance and clinical factors associated with a subcentimeter resection of colorectal liver metastases. Ann Surg Oncol. 2005;12:1–7.
Are C et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246:295–300.
Kokudo N et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg. 2002;137:833–40.
Montalti R et al. Impact of surgical margins on overall and recurrence-free survival in parenchymal-sparing laparoscopic liver resections of colorectal metastases. Surg Endosc. 1–12; 2015.
Tranchart H et al. Prognostic impact of positive surgical margins after resection of colorectal cancer liver metastases: reappraisal in the era of modern chemotherapy. World J Surg. 2013;37:2647–54.
Pawlik TM, Vauthey J-N. Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome. Ann Surg Oncol. 2008;15:677–9.
Muratore A et al. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol. 2010;17:1324–9.
Hamady ZZ et al. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule. Eur J Surg Oncol. 2006;32:557–63.
Nuzzo G et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery. 2008;143:384–93.
De Haas RJ et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626–36.
Bodingbauer M et al. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg. 2007;94:1133–8.
Inoue Y et al. Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer. J Gastrointest Surg. 2012;16:1171–80.
Nanko M et al. Micrometastatic colorectal cancer lesions in the liver. Surg Today. 1998;28:707–13.
Pawlik TM et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–24.
Sadot E et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015;262:476–85. This study evaluates the relationship between resection margin width and overall survival utilizing high-resolution histologic distance measurements. Resection margin width is independently associated with overall survival, however, resection should not be precluded if narrow margins are anticipated, as submillimeter margin clearance is associated with improved survival. The authors speculate that the prolonged overall survival observed with submillimeter margins is likely a microscopic surrogate for the biologic behavior of a tumor.
Eveno C et al. Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford). 2013;15:359–64.
Ng JKS et al. Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer. 2008;112:362–71.
Mentha G, Majno P E, Andres A. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J. 2006;93:872–78.
Tanaka K, Nojiri K, Kumamoto T, Takeda K, Endo I. R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy. Eur J Surg Oncol. 2011;37:336–43.
Ayez N et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol. 2012;19:1618–27.
Truant S et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford). 2015;17:176–84. The authors sought to assess the impact of a positive surgical margin (R1) on survival in the era of modern chemotherapy. Interestingly, they authors noted that the difference in progression-free survival between the negative surgical margin (R0) and positive surgical margin (R1), in their cohort, disappeared following the more systematic administration of chemotherapy since 2005.
Figueras J et al. Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections. Ann Oncol. 2007;18:1190–5.
Konopke R et al. Resection of colorectal liver metastases: is a resection margin of 3 mm enough? A multicenter analysis of the GAST study group. World J Surg. 2008;32:2047–56.
Busquets J, Pelaez N, Alonso S, Grande L. The study of cavitational ultrasonically aspirated material during surgery for colorectal liver metastases as a new concept in resection margin. Ann Surg. 2006;244:634–5.
SHammond J, Muirhead W, Zaitoun AM, Cameron IC, Lobo DN. Comparison of liver parenchymal ablation and tissue necrosis in a cadaveric bovine model using the Harmonic Scalpel, the LigaSure, the Cavitron Ultrasonic Surgical Aspirator and the Aquamantys devices. HPB (Oxford). 2012;14:828–32.
Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.
Angelsen J-H, Horn A, Eide GE, Viste A. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol. 2014;12:127.
John SK et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30:293–301.
Poultsides G, Brown M, Orlando 3rd R. Hand-assisted laparoscopic management of liver tumors. Surg Endosc. 2007;21:1275–9.
Poultsides GA, Schulick RD, Pawlik TM. Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome. HPB. 2010;12:43–9.
Margonis GA, Spolverato G, Kim Y, Ejaz A, Pawlik TM. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg. 2015;19:699–707. This study evaluates recurrence and survival among patients who underwent intraoperative margin re-resection for colorectal cancer liver metastasis. In the era of modern systemic chemotherapy, the impact of margin status on outcome may be minimal. Margin re-resection to achieve R0 status does not improve long-term outcomes.
Khan SA, Matthews JB. Intraoperative margin re-resection for colorectal cancer liver metastases. Hepatobiliary Surg Nutr. 2013;2:108–12.
Wray CJ et al. Intraoperative margin re-resection for colorectal liver metastases. J Surg Educ. 2007;64:150–7.
Pandanaboyana S et al. Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis. Ann Surg Oncol. 2015;22:173–9. The authors of this study noted that microscopic margin positive resections (R1) increase the likelihood of recurrence in the liver and redo liver surgery. Furthermore the use of neoadjuvant chemotherapy, in their study, does not seem to improve survival in margin positive patients on the contrary it may have adverse outcome on disease free survival.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Alessandro Paniccia and Richard D. Schulick declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Colorectal Cancer Hepatic Metastases
Rights and permissions
About this article
Cite this article
Paniccia, A., Schulick, R.D. Surgical Margin in Hepatic Resections for Colorectal Metastasis: Should We Care?. Curr Colorectal Cancer Rep 12, 180–187 (2016). https://doi.org/10.1007/s11888-016-0323-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11888-016-0323-8